Study of CYP2C19 gene polymorphism in patients with cardiovascular and cerebrovascular diseases in Shanxi Province

doi:10.3877/cma.j.issn.2095-5820.2023.03.007

Abstract

Abstract:

Objective

Study the gene polymorphism of CYP2C19 in patients with cardiovascular and cerebrovascular diseases, analyze whether it is related to age and sex differences, and provide guidance for the individualized medication of clopidogrel.

Methods

Using real-time PCR, to monitor the genotype of CYP2C19 for 776 patients with cardiovascular and cerebrovascular diseases,who were considered to receive clopidogrel antithrombotic therapy,and the correlation between age, sex and their genetic polymorphisms was analyzed.

Results

Four genotypes were detected, which were CYP2C19*1/*1 (42.14%), *2/*2 (10.82%), *3/*3 (1.03%) and *3/*17 (46.01%). The three metabolic phenotypes were extensive metabolizer/EM (42.14%), intermediata metabolizer/IM (46.01%) and poor metabolizer/PM (11.85%). The metabolic phenotypes were similar to those of related report. The CYP2C19 genotype and metabolic phenotype was associated with an increased rate of male and female patients (all P＜0.05). There was no significant difference among patients of different age in CYP2C19 genotype and metabolic phenotype (all P＜0.05).

Conclusions

The patients with cardiovascular and cerebrovascular diseases in Shanxi are mainly EM and IM patients, which is in line with Asian population distribution, and the number of patients with genotype CYP2C19 *1/*1 and *3/*17 is the largest. At the same time, it can not be considered to be guided according to the differences of CYP2C19 genotype, metabolic phenotype and the age, sex in drug use, still need according to the patient's own situation to give individualized medication treatment.

Key words: CYP2C19, clopidogrel, genetic polymorphism, individualized medication

Yulu Ren, Shuning Wang, Kai Chang, Miao Yang. Study of CYP2C19 gene polymorphism in patients with cardiovascular and cerebrovascular diseases in Shanxi Province[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(03): 163-166,180.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2023.03.007

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2023/V11/I03/163

Figures/Tables 3

References 29

1	HASAN M S, BASRI H B, HIN L P, et al. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: Why the Asian population requires special attention[J]. The international journal of neuroscience, 2013, 123(3): 143-154.
2	杨瑞, 刘慧, 陈泽姮, 等. 临床药师基于CYP2C19基因检测指导氯吡格雷个体化用药及其疗效评价[J]. 中国临床药理学与治疗学, 2019, 24(8): 938-943.
3	董结芬. 药物基因检测指导氯吡格雷的临床用药价值研究[J]. 深圳中西医结合杂志, 2020, 30(15): 96-97.
4	CHEN D Y, WANG C Y, WEN M S, et al. Paraoxonase-1 is not a maor determinant of stent thrombosis in a Taiwanese population[J]. PLoS One, 2012, 7(6): e39178.
5	HULOT J S, BURA A, VILLARD E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood, 2006, 108(7): 2244-2247.
6	COLLET J P, HULO J S, PENA A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study[J]. Lancet (London, England), 2009, 373(9660): 309-317.
7	MEGA J L, CLOSE S L, WIVIOTT S D, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J]. New England journal of medicine, 2009, 360: 354-362.
8	SHULDINER A R, O'CONNELL J R, BLIDEN K P, et al. Association of cytochrome P450 2C19 genotype with the antiplateleteffect and clinical effcacy of clopidogrel therapy[J]. The journal of the American medical association, 2009, 302(8): 849-857.
9	FRÉRE C, CUISSET T, GABORIT B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome[J]. Journal of thrombosis and haemostasis, 2009, 7(8): 1409-1411.
10	SIBBING D, GEBHARD D, KOCH W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy[J]. Journal of thrombosis and haemostasis, 2010, 8(8): 1685-1693.
11	TIROCH KA, SIBBING D, KOCH W, et al. Protective effect of the CYP2C19*17 polymorphismwith increased activation of clopidogrel on cardiovascular events[J]. American heart journal, 2010, 160(3): 506-512.
12	邵明凤. 内科急性心绞痛患者使用氯吡格雷治疗的临床效果研究[J]. 系统医学, 2022, 7(14): 103-106.
13	栾鹏娇. 氯吡格雷对冠心病介入治疗后发生心血管不良事件的预防效果观察[J]. 中国医药指南, 2022, 20(31): 95-97.
14	GOLUKHOVA E Z, RYABININA M N, BULAEVA N I, et al. Clopidogrel response variability: Impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting[J]. American journal of therapeutics, 2015, 22(3): 222-230.
15	付梦璐, 董若兰, 凃玲, 等. 氯吡格雷抵抗研究进展[J]. 医药导报, 2018, 37(2): 139-145.
16	FEFER P, MATETZKY S. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature[J]. Thromb haemost, 2011, 106(2): 203-210.
17	MEGA J L, SIMON T, Collet J P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis[J]. The journal of the American medical association, 2010, 304(16): 1821-1830.
18	刘龙梅, 周双艳, 王仲朝, 等. 太原地区汉族冠心病患者CYP2C19基因多态性研究[J]. 实用检验医师杂志, 2018, 10(4): 216-219.
19	张红楠, 王强, 朱晓红, 等. CYP2C19基因指导冠心病患者经皮冠状动脉介人术后抗血小板药合理应用[J]. 药学实践杂志, 2018, 36(6): 518-521.
20	DEHBOZORGI M, KAMALIDEHGHAN B, HOSSEINI I, et al. Prevalence of the CYP2C192 (681 G＞A), 3(636 G＞A) and*17 (-806 C＞T) alleles among an Iranian population of different ethnicities[J]. Molecular medicine reports, 2018, 17(3): 4195-4202.
21	郭秀彩, 银雪艳, 许启荣, 等. CYP2C19和ABCB1基因检测指导患者氯吡格雷个体化给药[J]. 今日药学, 2020, 30(1): 36-39.
22	WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. The New England journal of medicine, 2007, 357(20): 2001-2015.
23	刘新正, 李晓龙. 血栓弹力图监测抗血小板药物抑制率在老年急性冠脉综合征患者临床治疗中的价值[J]. 临床血液学杂志, 2020, 33(6): 425-427.
24	司家章, 冯雪茹, 刘梅林. 老年患者服用不同剂量氯吡格雷、替格瑞洛的反应性及安全性分析[J]. 临床心血管病杂志, 2022, 38(6): 460-466.
25	梁晶星, 陈芳, 梁启明. 应用血栓弹力图比较替格瑞洛及氯吡格雷治疗急性冠脉综合征患者的临床疗效[J]. 基层医学论坛, 2022, 26(22): 22-24.
26	刘福波, 杨琨. 替格瑞洛在冠心病介入治疗中的应用及对患者凝血功能的影响[J]. 吉林医学, 2022, 43(6): 1599-1601.
27	钟诗龙, 韩雅玲, 陈纪言, 等. 氯吡格雷抗血小板治疗个体化用药基因型检测指南解读[J]. 中国实用内科杂志, 2015, 35(1): 38-41.
28	唐晓春, 刘猛, 丁俭, 等. 急性脑梗死患者氯吡格雷基因代谢类型与氯吡格雷抵抗的关系[J]. 江苏医药, 2020, 46(5): 483-486.
29	SCOTT S A, SANGKUHL K, STEIN C M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013update[J]. Clinical pharmacology and therapeutics, 2013, 94(3): 317-323.

性别	例数/例	基因型				代谢表型
性别	例数/例	1/1	2/2	3/3	3/17	EM	PM	IM
男	511	210（41.10）	46（9.00）	5（0.98）	250（48.92）	210（41.10）	51（9.98）	250（48.92）
女	265	117（44.15）	38（14.34）	3（1.13）	107（40.38）	117（44.15）	41（15.47）	107（40.38）
χ²值		7.780				7.595
P值		P＜0.05				P＜0.025

性别	例数/例	基因型				代谢表型
性别	例数/例	1/1	2/2	3/3	3/17	EM	PM	IM
男	511	210（41.10）	46（9.00）	5（0.98）	250（48.92）	210（41.10）	51（9.98）	250（48.92）
女	265	117（44.15）	38（14.34）	3（1.13）	107（40.38）	117（44.15）	41（15.47）	107（40.38）
χ²值		7.780				7.595
P值		P＜0.05				P＜0.025

年龄	例数/例	基因型				代谢表型
年龄	例数/例	1/1	2/2	3/3	3/17	EM	PM	IM
＜40岁	8	5（62.50）	0（0.00）	0（0.00）	3（37.50）	5（62.50）	0（0.00）	3（37.50）
40~60岁	255	106（41.57）	28（10.98）	3（1.18）	118（46.27）	106（41.57）	31（12.16）	118（46.27）
61~80岁	481	202（42.00）	53（11.02）	5（1.04）	221（45.95）	202（42.00）	58（12.06）	221（45.95）
＞80岁	32	14（43.75）	3（9.38）	0（0.00）	15（46.87）	14（43.75）	3（9.38）	15（46.87）
χ²值		2.38				2.12
P值		0.975＜P＜0.99				0.900＜P＜0.950

年龄	例数/例	基因型				代谢表型
年龄	例数/例	1/1	2/2	3/3	3/17	EM	PM	IM
＜40岁	8	5（62.50）	0（0.00）	0（0.00）	3（37.50）	5（62.50）	0（0.00）	3（37.50）
40~60岁	255	106（41.57）	28（10.98）	3（1.18）	118（46.27）	106（41.57）	31（12.16）	118（46.27）
61~80岁	481	202（42.00）	53（11.02）	5（1.04）	221（45.95）	202（42.00）	58（12.06）	221（45.95）
＞80岁	32	14（43.75）	3（9.38）	0（0.00）	15（46.87）	14（43.75）	3（9.38）	15（46.87）
χ²值		2.38				2.12
P值		0.975＜P＜0.99				0.900＜P＜0.950

[1]	Yujin Zhang, Hongwei Liu, Huai Bai, Ping Fan. Research progress on relationship between paraoxonase 1 and polycystic ovary syndrome [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(02): 249-253.
[2]	Qi Xiao, Yansong Pu, Qingguo Du, Xianglong Duan, Xiaofan Li, Ni Yang, Fei Xue. Association between SDF-1α gene polymorphism and risk of gastric cancer in the Han nationality of Northwest China [J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(04): 258-262.
[3]	Baolei Guo, Weiguo Fu, Daqiao Guo, Zhenyu Shi, Lixin Wang, Xiao Tang, Weimiao Li. Association of CYP2C19 genotype and platelet responsiveness with clinical efficacy of clopidogrel therapy in patients with arteriosclerosis obliterans after stent implantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(01): 13-17.
[4]	Chao Ma, Yan Jin, Xibin Duan, Wei Cao, Guochen Xing, Shanyong Yi, Xuemin Li, Xiaofei Wang. Influence of drug transporters polymorphisms on severe adverse reaction caused by irinotecan in colorectal cancer patients [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(03): 257-261.
[5]	Hongda Liu, Xiangzhong Shao, Lin Li, Xiaowei Xu. Correlation between CYP2C19 gene polymorphism and clopidogrel resistance in patients with atherosclerotic thrombotic cerebral infarction in Hai'an area [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(04): 234-240.
[6]	Hongli Yang, Xiaofei Lei, Kun Li, Changqing Xu, Jing Yang. Association between tumor necrosis factor-α gene polymorphisms and susceptibility to irritable bowel syndrome: a Meta-analysis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2017, 07(05): 211-219.
[7]	Yan He, Bao Yu, Jiagui Huang, Jian Huang, Yong Hu, Yanxin Jin, Li Chen, Yanling Gao. Gene-oriented individualized medication in hypertension patients [J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(12): 679-683.
[8]	Ying Zhao, yan Zhou, Lan Zhang, Yinghui Ju, Chunyan Zhang, Wei Guo, Baishen Pan, Daqiao Guo. Association between CYP2C19 genotype and the clinical efficacy of clopidogrel therapy in Chinese patients with arteriosclerosis obliterans after stent implantation [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2015, 03(04): 225-229.
[9]	Yanru Yin, Guorong Liu, Xiaohua Pan. Analysis of CYP2C19 gene polymorphism in ischemic stroke patients in Baotou area, Inner Mongolia [J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(01): 46-50.
[10]	Shuyi Zhang, Shusen Wang, Mo Dong, Lei Shi, Yanru Li, Wen Li. The study of prevention effect of esomeprazole on clopidogrel-induced gastric mucosal injury [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2018, 05(01): 38-40.
[11]	Yi Wu, Xiaoyan Wu, Yu Zhang. Effects Of CYP2C19 Gene Polymorphisms On Coadministration Therapies Related To PPIs In The Elderly [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2015, 02(03): 22-29.
[12]	Lihua Jiang, Ling Guan, Jiali Huang, Xinliang Han. Effect of atorvastatin calcium combined with ticagrelor on patients with coronary heart disease and hyperlipidemia and the effect of serum cytokines [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2021, 07(03): 165-169.
[13]	Xuping Zhang, Jiacheng Liu, Ge Zhang, Yanjiao Du, Shao Li, Dandan Shang, Hao Wang, Yan Li, Zhihui Duan. CYP2C19 gene polymorphism combined with thromboelastogram-guided antiplatelet therapy for patients with the large artery atherosclerosis and non-disabling ischemic cerebrovascular events (NICE) [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 477-481.

Please choose a citation manager

Content to export